Evidence map›Paper›PMID 33097001›Full record

ArticleBMC nephrology2020

Cardiovascular outcomes following percutaneous coronary intervention with drug-eluting balloons in chronic kidney disease: a retrospective analysis.

Michael Jonas, Maayan Kagan, Gal Sella, Dan Haberman, Gil Chernin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Michael JonasHeart Institute, Kaplan Medical Center, Hebrew University School of Medicine, Rehovot, Israel.
Maayan KaganDepartment of Nephrology and Hypertension, Kaplan Medical Center, Hebrew University School of Medicine, Pasternak St. POB1, 76100, Rehovot, Israel.
Gal SellaHeart Institute, Kaplan Medical Center, Hebrew University School of Medicine, Rehovot, Israel.
Dan HabermanHeart Institute, Kaplan Medical Center, Hebrew University School of Medicine, Rehovot, Israel.
Gil CherninDepartment of Nephrology and Hypertension, Kaplan Medical Center, Hebrew University School of Medicine, Pasternak St. POB1, 76100, Rehovot, Israel. Chernin4@gmail.com.ORCID 0000-0001-7514-156X
Kaplan Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic kidney disease (CKD) is associated with poorer outcomes following percutaneous coronary intervention (PCI) with drug-eluting stents. Drug-eluting balloons are used for in-stent restenosis and selected cases of de-novo coronary lesions. Little is known regarding the outcomes of individuals with CKD who undergo PCI with drug-eluting balloons. The goal of this study was to assess outcomes of PCI with drug-eluting balloons in individuals with CKD.

methodsIn a retrospective analysis, outcomes of PCI with drug-eluting balloons were compared between 101 patients with CKD and 261 without CKD. CKD was defined as estimated glomerular filtration rate < 60 ml/min/1.73m

resultsRates of major adverse cardiac events (MACE) and myocardial infarction were higher in patients with than without CKD: 23.8% vs. 13.8%, P < 0.005 and 15.9% vs. 3.8%, P < 0.001, respectively. Rates of target lesion revascularization were similar, 14.9 and 11.5%, respectively, P = 0.4. Shorter duration of dual anti-platelet therapy was observed among patients with than without CKD (10.0 + 3.4 vs. 10.9 + 3.7 months, P < 0.05). First-year hemorrhage episodes were similar in the two groups (0.08 ± 0.4 and 0.03 ± 0.2, respectively, P = 0.2). In a multivariate regression analysis, CKD was associated with increased risks of first year MACE (OR 2.1; 95% confidence interval 1.0-4.3, P < 0.001).

conclusionsPCI with drug-eluting balloons was associated with increased cardiovascular morbidity and mortality in patients with than without CKD. However, rates of target lesion revascularization were similar in the two groups. Shorter duration of dual anti-platelet therapy was observed in the CKD group.

Indexed as

AgedCoronary Artery DiseaseDrug Administration ScheduleDrug-Eluting StentsFemaleHumansMaleMiddle AgedPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPostoperative ComplicationsRegression AnalysisRenal Insufficiency, ChronicRetrospective StudiesRisk FactorsTreatment OutcomePlatelet Aggregation InhibitorsCardiovascular mortalityChronic kidney diseaseDrug-eluting balloonsDrug-eluting stentsDual anti-platelet therapyIn-stent restenosisIschemic heart diseasePercutaneous coronary interventionTarget lesion revascularization

Identifiers

PMID33097001
PMCPMC7583297
OpenAlexW3094356163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.